Janus kinase 2 mutations in cases with BCR-ABL-negative chronic myeloproliferative disorders from Turkey

Objective: We aimed to investigate the frequency of Janus kinase 2 ( JAK2) mutations in cases with chronic myeloproliferative disorders (CMDs), and the relationship between the presence of JAK2 mutation and leukocytosis and splenomegaly, retrospectively. Materials and Methods: Patients, who were dia...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Ismail Yildiz, Osman Yokuş, Habip Gedik
Formato:	article
Lenguaje:	EN
Publicado:	Thieme Medical and Scientific Publishers Pvt. Ltd. 2017
Materias:	chronic myeloproliferative disorders janus kinase 2 v617f mutation leukocytosis splenomegaly Medicine R
Acceso en línea:	https://doaj.org/article/a157274e74a74057940a257df7922f66
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:a157274e74a74057940a257df7922f66
record_format	dspace
spelling	oai:doaj.org-article:a157274e74a74057940a257df7922f662021-12-02T16:37:41ZJanus kinase 2 mutations in cases with BCR-ABL-negative chronic myeloproliferative disorders from Turkey2231-07702249-446410.4103/2231-0770.197511https://doaj.org/article/a157274e74a74057940a257df7922f662017-01-01T00:00:00Zhttp://www.thieme-connect.de/DOI/DOI?10.4103/2231-0770.197511https://doaj.org/toc/2231-0770https://doaj.org/toc/2249-4464Objective: We aimed to investigate the frequency of Janus kinase 2 ( JAK2) mutations in cases with chronic myeloproliferative disorders (CMDs), and the relationship between the presence of JAK2 mutation and leukocytosis and splenomegaly, retrospectively. Materials and Methods: Patients, who were diagnosed with BCR-ABL-negative CMDs according to diagnosis criteria of the World Health Organization and followed up at the hematology clinic between 2013 and 2015, were investigated in terms of the frequency of JAK2 mutation in cases with CMDs, and the relationship between the presence of JAK2 mutation and leukocytosis and splenomegaly, retrospectively. Results: In total, 100 patients, who were diagnosed with BCR-ABL-negative CMDs, were evaluated retrospectively. The mean age of the patients with JAK2 positivity was significantly higher compared to patients with negative. JAK2-positivity rates in the age groups were significantly different. Gender, diagnosis, splenomegaly, and leukocytosis were not statistically different for JAK2 positivity between the groups. Conclusion: JAK2 V617F mutation is more commonly seen in older age as a risk for complications related to CDMS. Splenomegaly and leukocytosis are not associated with JAK2 V617F mutation.Ismail YildizOsman YokuşHabip GedikThieme Medical and Scientific Publishers Pvt. Ltd.articlechronic myeloproliferative disordersjanus kinase 2 v617f mutationleukocytosissplenomegalyMedicineRENAvicenna Journal of Medicine, Vol 07, Iss 01, Pp 28-31 (2017)
institution	DOAJ
collection	DOAJ
language	EN
topic	chronic myeloproliferative disorders janus kinase 2 v617f mutation leukocytosis splenomegaly Medicine R
spellingShingle	chronic myeloproliferative disorders janus kinase 2 v617f mutation leukocytosis splenomegaly Medicine R Ismail Yildiz Osman Yokuş Habip Gedik Janus kinase 2 mutations in cases with BCR-ABL-negative chronic myeloproliferative disorders from Turkey
description	Objective: We aimed to investigate the frequency of Janus kinase 2 ( JAK2) mutations in cases with chronic myeloproliferative disorders (CMDs), and the relationship between the presence of JAK2 mutation and leukocytosis and splenomegaly, retrospectively. Materials and Methods: Patients, who were diagnosed with BCR-ABL-negative CMDs according to diagnosis criteria of the World Health Organization and followed up at the hematology clinic between 2013 and 2015, were investigated in terms of the frequency of JAK2 mutation in cases with CMDs, and the relationship between the presence of JAK2 mutation and leukocytosis and splenomegaly, retrospectively. Results: In total, 100 patients, who were diagnosed with BCR-ABL-negative CMDs, were evaluated retrospectively. The mean age of the patients with JAK2 positivity was significantly higher compared to patients with negative. JAK2-positivity rates in the age groups were significantly different. Gender, diagnosis, splenomegaly, and leukocytosis were not statistically different for JAK2 positivity between the groups. Conclusion: JAK2 V617F mutation is more commonly seen in older age as a risk for complications related to CDMS. Splenomegaly and leukocytosis are not associated with JAK2 V617F mutation.
format	article
author	Ismail Yildiz Osman Yokuş Habip Gedik
author_facet	Ismail Yildiz Osman Yokuş Habip Gedik
author_sort	Ismail Yildiz
title	Janus kinase 2 mutations in cases with BCR-ABL-negative chronic myeloproliferative disorders from Turkey
title_short	Janus kinase 2 mutations in cases with BCR-ABL-negative chronic myeloproliferative disorders from Turkey
title_full	Janus kinase 2 mutations in cases with BCR-ABL-negative chronic myeloproliferative disorders from Turkey
title_fullStr	Janus kinase 2 mutations in cases with BCR-ABL-negative chronic myeloproliferative disorders from Turkey
title_full_unstemmed	Janus kinase 2 mutations in cases with BCR-ABL-negative chronic myeloproliferative disorders from Turkey
title_sort	janus kinase 2 mutations in cases with bcr-abl-negative chronic myeloproliferative disorders from turkey
publisher	Thieme Medical and Scientific Publishers Pvt. Ltd.
publishDate	2017
url	https://doaj.org/article/a157274e74a74057940a257df7922f66
work_keys_str_mv	AT ismailyildiz januskinase2mutationsincaseswithbcrablnegativechronicmyeloproliferativedisordersfromturkey AT osmanyokus januskinase2mutationsincaseswithbcrablnegativechronicmyeloproliferativedisordersfromturkey AT habipgedik januskinase2mutationsincaseswithbcrablnegativechronicmyeloproliferativedisordersfromturkey
_version_	1718383647651790848

Janus kinase 2 mutations in cases with BCR-ABL-negative chronic myeloproliferative disorders from Turkey

Ejemplares similares